Author: Kathryn Atkins

Figure 1: Canonical Src regulation involves the transition from an inactive closed state to an active open form.

Targeting the Src N-Terminal Regulatory Element in Cancer

June 9, 2023

“[...] Src is a recognized oncotarget.” BUFFALO, NY- June 9, 2023 – A new research perspective was published in Oncotarget's Volume 14 on May 19, 2023, entitled, “Targeting the Src… read more

Figure 1: Response to docetaxel in second or third line treatment for non-small cell lung cancer after a treatment with chemo-immunotherapy.

Oncotarget

Value of Chemotherapy Post Immunotherapy in Stage IV Non-Small Cell Lung Cancer

June 7, 2023

“[...] large multicenter prospective randomized trials are needed to provide the clinical evidence for the use of [chemotherapy] in second line and third-line post [immunotherapy] failure.” Listen to an audio… read more

Association of mutation and expression of the brother of the regulator of imprinted sites (BORIS) gene with breast cancer progression

Oncotarget

BORIS Gene Mutation and Expression: Link to Breast Cancer Progression

June 5, 2023

“The current study analyzed the correlation between BORIS mutations and the expression of the protein in breast cancer cases.” Listen to an audio version of this press release BUFFALO, NY-… read more

Figure 1: MALAT1-ASO specifically targets MALAT1-lncRNAs.

Oncotarget

Deconstructing the Role of MALAT1 in MAPK-Signaling in Melanoma

May 30, 2023

“In this study, we present novel transcriptional dependencies between MALAT1 and MAPK-pathway-associated genes in melanoma.” Listen to an audio version of this press release BUFFALO, NY- May 30, 2023 –… read more

Oncotarget

HER3: Survival Pathway and Therapeutic Target in Metastatic Colorectal and Pancreatic Cancer

May 24, 2023

“[...] we discovered that the surrounding liver EC microenvironment plays a key role in activating HER3 and promoting cell survival in mCRC and mPDAC [...].” Listen to an audio version… read more

Figure 7: Schematic demonstrating the role of GPR141 in mediating breast cancer development and progression.

Oncotarget

GPR141 Regulates Breast Cancer Progression via Oncogenic Mediators and The p-mTOR/p53 Axis

May 22, 2023

“This research uncovers GPR141 as a stimulator of breast tumorigenesis and metastasis, making it a candidate target for breast cancer therapeutics.” Listen to an audio version of this press release… read more

Figure 1: Inhibitors of mitochondrial respiration.

Oncotarget

Targeting Cellular Respiration as a Therapeutic Strategy in Glioblastoma

May 19, 2023

“Here, we provide a brief overview of the status quo of targeting mitochondrial energy metabolism in glioblastoma and highlight a novel combination therapy.” Listen to an audio version of this… read more

Oncotarget

Impact Journals at SSP 45th Annual Meeting

May 17, 2023

Impact Journals (Oncotarget's publisher) is proud to participate at the Society for Scholarly Publishing (SSP) 45th Annual Meeting, which convenes May 31–June 2, 2023, in Portland, Oregon. Listen to an… read more

Figure 2: Polyclonal, Clonal and Restricted Repertoire Phenotypes in Clonality Testing.

Oncotarget

Automated, Accurate Reporting for NGS-Based Clonality Testing

May 16, 2023

“[...] we have developed a fully automated calling algorithm for determining B and T cell clonality from NGS [next-generation sequencing] data, with greater sensitivity than previously developed models.” Listen to… read more

Figure 3: Combined analysis of kinase expression in tumors with cell line dependency to identify new gene targets. therapeutic targeting

Oncotarget

Using Cancer Proteomics Data to Identify Gene Candidates for Therapeutic Targeting

May 10, 2023

“[...] we consider some public molecular resources, including proteomics datasets, that may be leveraged to help identify gene candidates for therapeutic targeting in cancer.” Listen to an audio version of… read more